title: Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
abstract: OBJECTIVE
  Patients with inflammatory bowel diseases are suggested to have an increased risk of acute pancreatitis. Although azathioprine and glucocorticoids are risk factors for acute pancreatitis, the relation is poorly understood, in particular the role of 5-aminosalicylic acid and sulfasalazine treatment. To clarify these relations, we conducted a population-based case-control study.
  
  
  METHODS
  We identified 1,590 incident cases of acute pancreatitis from the Hospital Discharge Registry of the North Jutland County of Denmark from 1991 to 2002, and selected 10 controls per case (N = 15,913) from the Central Personal Registry, matched by age and gender. Among cases and controls, we identified patients with inflammatory bowel diseases. Data on drug use were extracted from a Pharmaco-epidemiological Prescription Database.
  
  
  RESULTS
  Adjusted odds ratios for acute pancreatitis in patients with Crohn's disease and ulcerative colitis were 3.7 (95% confidence interval (CI), 1.9-7.6) and 1.5 (95% CI, 0.7-3.6), respectively. In all patients treated with 5-aminosalicylic acid and sulfasalazine the adjusted odds ratios for acute pancreatitis were 0.7 (95% CI, 0.4-2.2) and 1.5 (95% CI, 0.4-5.2), respectively. Restricted to patients with inflammatory bowel diseases only, the adjusted odds ratios for acute pancreatitis in patients exposed to 5-aminosalicylic acid and sulfasalazine were 0.7 (95% CI, 0.1-3.8) and 0.6 (95% CI, 0.1-6.7), respectively.
  
  
  CONCLUSIONS
  We found a nearly four-fold increased risk of acute pancreatitis in patients with Crohn's disease and a 1.5-fold increased risk for ulcerative colitis. In patients with inflammatory bowel diseases, the use of 5-aminosalicylic acid or sulfasalazine was not associated with increased risk of acute pancreatitis.
authors.affiliation: Department of Clinical Epidemiology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.
authors.forename: Estrid Muff
authors.initials: EM
authors.lastname: Munk
authors.forename: Lars
authors.initials: L
authors.lastname: Pedersen
authors.forename: Andrea
authors.initials: A
authors.lastname: Floyd
authors.forename: Bente
authors.initials: B
authors.lastname: Nørgård
authors.forename: Henrik Højgaard
authors.initials: HH
authors.lastname: Rasmussen
authors.forename: Henrik T
authors.initials: HT
authors.lastname: Sørensen
mesh_terms: D000208:Acute Disease; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D016022:Case-Control Studies; D016001:Confidence Intervals; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010186:Pancreatic Function Tests; D010195:Pancreatitis / Q000139:chemically induced* / Q000453:epidemiology* / Q000503:physiopathology; D015995:Prevalence; D011336:Probability; D012042:Registries; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000636:Aminosalicylic Acids; D012460:Sulfasalazine